about
Cabozantinib in the treatment of advanced renal cell carcinoma: design, development, and potential place in the therapyHow do the results of the RADIANT trials impact on the management of NET patients? A systematic review of published studiesLymphoma Immunotherapy: Current StatusIncidence and relative risk of grade 3 and 4 diarrhoea in patients treated with capecitabine or 5-fluorouracil: a meta-analysis of published trialsPredictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis.Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockadeMET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer.Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumorsFluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancerConcomitant EML4-ALK rearrangement and EGFR mutation in non small cell lung cancer patients: A literature review of 100 cases."Waiting and the waiting room: how do you experience them?" emotional implications and suggestions from patients with cancer.Analysis of plasma cytokines and angiogenic factors in patients with pretreated urothelial cancer receiving Pazopanib: the role of circulating interleukin-8 to enhance the prognostic accuracyEverolimus and temsirolimus are not the same second-line in metastatic renal cell carcinoma. A systematic review and meta-analysis of literature data.Phase II studies of BBR3464, a novel tri-nuclear platinum complex, in patients with gastric or gastro-oesophageal adenocarcinoma.A proper schedule of weekly paclitaxel and gemcitabine combination is highly active and very well tolerated in NSCLC patients.Optimizing clinical care in patients with advanced soft tissue sarcoma: a phase II study of a new schedule of high-dose continuous infusion ifosfamide and doxorubicin combination.Activity of temozolomide in patients with advanced chemorefractory colorectal cancer and MGMT promoter methylation.Long-term efficacy and safety outcomes of modified (simplified) MVAC (methotrexate/vinblastine/doxorubicin/cisplatin) as frontline therapy for unresectable or metastatic urothelial cancer.PF-03446962, a fully-human monoclonal antibody against transforming growth-factor β (TGFβ) receptor ALK1, in pre-treated patients with urothelial cancer: an open label, single-group, phase 2 trial.Activity and safety of RAD001 (everolimus) in patients affected by biliary tract cancer progressing after prior chemotherapy: a phase II ITMO study.Real-world study of everolimus in advanced progressive neuroendocrine tumors.A Phase I Study of the Anti-Activin Receptor-Like Kinase 1 (ALK-1) Monoclonal Antibody PF-03446962 in Patients with Advanced Solid Tumors.Clinical Response of Carcinomas Harboring the BRD4-NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628Phase I study of PF-03446962, a fully human monoclonal antibody against activin receptor-like kinase-1, in patients with hepatocellular carcinoma.Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial.Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomasStudy design and clinical evidence in mRCC: can we save axitinib as a first-line therapy?Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer.Ifosfamide in the elderly: clinical considerations for a better drug management.FOLFOX-4 chemotherapy for patients with unresectable or relapsed peritoneal pseudomyxoma.Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma.Circulating biomarkers in advanced colorectal cancer patients randomly assigned to three bevacizumab-based regimensPharmacogenetic determinants of anti-cancer drug activity and toxicity.Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production.Targeted treatments in advanced renal cell carcinoma: focus on axitinib.Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.Bevacizumab treatment in the elderly patient with metastatic colorectal cancer.Vatalanib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: final results of a phase II study.A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumorsGain of ALK gene copy number may predict lack of benefit from anti-EGFR treatment in patients with advanced colorectal cancer and RAS-RAF-PI3KCA wild-type status
P50
Q26741450-E56A30C7-8C1E-4665-83A9-20806B507CF9Q26750748-8AF1A460-C1E6-41C6-9BD8-12D42BBBFD5BQ26782902-C680DC40-4313-4BA2-808F-2396EE2952E4Q27028095-5C8CDDEF-A3D4-415E-9752-74B4FC3B8528Q27853129-C38E7550-0AD5-4744-96BF-80C2B873740DQ27853295-8713781C-A9C1-4B1C-8236-77AAFFA913B5Q27853393-E15BFBC1-4036-4F8D-86ED-427DBFD6B605Q28247372-C9D54EDD-A89C-4597-9368-93079000EC8FQ28305293-DA318A13-C61A-4C90-88EF-469D86DB55E9Q30234436-A1BD7500-A02D-43A5-876A-32F84A2AB08AQ30386329-3D7C2102-580F-45BF-95CB-1D127B2F6972Q30563774-FD7113CC-2C47-44D9-BAEB-0D995763F3D6Q30845230-E4571A57-5471-499F-9670-DA6847410CAAQ33361959-BBA12872-9768-4B4C-A9E3-445962B1276DQ33372899-7B6E5B55-2BE4-4A86-BA1C-2D096B7B13E1Q33395415-3BB7CD52-372C-4CD4-8CCE-D04F3DD61750Q33412380-453F4B18-31B6-4ABA-BDDA-2072A865102FQ33412487-EC496515-583D-4C72-ABDA-697739E0CA6DQ33413496-7390D85B-BF4C-4DB3-A9FB-352CA2A314E6Q33415304-8BF54A18-B763-4C5A-85CB-314924A1257AQ33417013-97559263-1336-4F78-826D-16D82ABA40D4Q33428300-EB0D98A3-E475-4C04-ACC1-7FDF4C835B04Q33430717-FE69F017-A8A3-4E13-B346-D01FB01BF4ADQ33433311-8226D8A3-8FB7-440C-99B1-C33CC451B645Q33435967-73539AA7-D57B-47EC-B34E-3182E1C8DED3Q33581027-E88FB6EC-FBB9-4B6C-917B-C104AE136CD9Q33631414-7EA57BDB-66B4-497B-83DC-49D49DC9FE1EQ33839100-DE20B7D9-60B7-48C8-A124-41FD39DBFDE5Q33875678-CAEADFA1-48D0-4B23-9E21-C3BFAA3DD7CEQ34005136-5B625DAB-5B04-415F-9D14-A47E581AF384Q34253748-137DADBE-463D-4E27-A658-B3FE43D278A4Q34309960-7CE86608-C7AC-40D1-ADCD-26C3D18CCABBQ34322733-79828FCF-DF6A-4892-9820-4EF9D8FE319DQ34556431-D3E5C421-A84E-48BD-9941-A70C2880FAB3Q34661185-ECB27F46-0611-4B1D-9FEB-36A5ABF6046AQ34664981-49EABF00-2007-419E-B7C5-B454887E3625Q34899949-338B05BB-CFB0-44B2-B19E-1102479BBC5EQ35034603-F775F3D1-3BF5-4360-A149-7AEE5D23284CQ35116704-0B4B75EF-7890-4F9E-AAA2-C8213BD232ADQ35137474-D7CD835F-DFDC-4A4B-A959-EF428E486E66
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Filippo de Braud
@ast
Filippo de Braud
@en
Filippo de Braud
@es
Filippo de Braud
@nl
Filippo de Braud
@sl
type
label
Filippo de Braud
@ast
Filippo de Braud
@en
Filippo de Braud
@es
Filippo de Braud
@nl
Filippo de Braud
@sl
altLabel
Filippo de Braud
@en
prefLabel
Filippo de Braud
@ast
Filippo de Braud
@en
Filippo de Braud
@es
Filippo de Braud
@nl
Filippo de Braud
@sl
P1053
B-9997-2017
P106
P1153
7004214793
P21
P31
P3829
P496
0000-0003-0103-730X